Uncommon mutations affect breast cancer prognosis

Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications. 


Read more

Argenx in US$1.6bn deal with J&J affiliate Janssen

Janssen affiliate Cilag GmbH International has licenced argenx’ anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.

Read more

Driver of GVHD after blood stem cell transplantation identified

Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.

Read more

Investors pool €27m for new Proteomics tech

UK-based biotech startup Fluidic Analytics has raised €27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners. 

Read more

Carbios set to build closed-loop PET plant

French Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios‘ groundbreaking enzymatic PET depolymerisation technology.

Read more

Adrenomed bags €24m in growth financing

German Adrenomed AG has bagged €24m in equity financing from HBM Healthcare Investments and Wellington Partners.

Read more

Roche targets asthma with inhalable JAK1 blocker

Researchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.

Read more

British F2G Biotech bags €24m

The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF). 

Read more

Sugar replacement slows cancer growth

Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.

Read more

Epigenetic drugs can increase tumour malignancy

Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.

Read more